Viatris Inc (Nasdaq:VTRS), a US-based global healthcare company, announced on Monday that the US Food and Drug Administration (FDA) has approved Iron Sucrose Injection, USP, an intravenous iron replacement product used to treat iron deficiency anaemia (IDA) in adult and paediatric patients (2 years of age and older) with chronic kidney disease (CKD).
IDA is a common complication of CKD and is associated with a significantly heightened risk of cardiovascular morbidity and higher mortality rates. Iron Sucrose Injection, USP, the first generic version of Venofer Injection, is expected to be available imminently in single dose vials in the following strengths: 50 mg/2.5mL, 100mg/5mL, and 200mg/10mL.
The FDA granted Viatris a competitive generic therapy (CGT) designation for iron sucrose 100 mg/5 mL and 200 mg/10 mL strengths. CGT designation allows for expedited review of generic versions of medications with 'inadequate generic competition.'
Viatris' generic iron sucrose injection gains US FDA approval
NRx Pharmaceuticals secures FDA Fast Track designation for NRX-100 in treating suicidal depression
IO Biotech reports Phase 3 trial results for Cylembio plus pembrolizumab in advanced melanoma
Novartis reports positive Phase III results for ianalumab in Sjögren's disease
Nuformix files US Orphan Drug Designation for NXP002 in Idiopathic Pulmonary Fibrosis
FDA grants priority review for GSK's gepotidacin gonorrhoea indication
RemeGen receives FDA approval to advance RC148 into Phase II trials for solid tumours
FDA lifts pause on Valneva's chikungunya vaccine IXCHIQ for elderly, updates prescribing information
Jazz Pharmaceuticals' Modeyso approved by US FDA for H3 K27M-mutant diffuse midline glioma treatment
Freenome and Exact Sciences agree licensing deal for CRC blood test
Intas Pharmaceuticals and Accord BioPharma acquire UDENYCA (pegfilgrastim-cbqv)
FDA approves Teva's AJOVY for paediatric episodic migraine prevention
Galapagos receives FDA RMAT designation for CAR-T therapy in mantle cell lymphoma